Shopping Cart
- Remove All
Your shopping cart is currently empty
(79)
Angiogenesis Filter
Angiogenesis Tyrosine Kinase/AdaptorsACK
(5)
ALK
(79)
BTK
(85)
Bcr-Abl
(79)
CSF-1R
(19)
DYRK
(26)
Discoidin Domain Receptor (DDR)
(12)
EGFR
(318)
Ephrin Receptor
(18)
FAK
(49)
FGFR
(119)
FLT
(114)
HER
(67)
Hck
(4)
IGF-1R
(62)
IGF-2R
(1)
JAK
(15)
PDGFR
(109)
PKA
(73)
PYK2
(8)
ROS Kinase
(22)
Src
(125)
Syk
(39)
TAM Receptor
(46)
Tie-2
(9)
Trk receptor
(59)
Tyrosine Kinases
(61)
VEGFR
(238)
c-Fms
(44)
c-Kit
(85)
c-Met/HGFR
(103)
c-RET
(42)
Src
Src kinase family is a family of non-receptor tyrosine kinases that includes nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. Frk has homologs in invertebrates such as flies and worms, and Src homologs exist in organisms as diverse as unicellular choanoflagellates, but the SrcA and SrcB subfamilies are specific to vertebrates. Src family kinases contain six conserved domains: a N-terminal myristoylated segment, a SH2 domain, a SH3 domain, a linker region, a tyrosine kinase domain, and C-terminal tail.
Staurosporine
Cited
T668062996-74-1
Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6 15 2 3 3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
Size
QTY
CitedeCF506
T84991914078-41-3
eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)
- $40
Size
QTY
Nintedanib Cited
T1777656247-17-5
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34 13 13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69 37 108 nM), PDGFRα, and PDGFRβ (IC50=59 65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
- $38
Size
QTY
CitedIbrutinib Cited
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
CitedDasatinib Cited
T1448302962-49-8
Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16 30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.
- $37
Size
QTY
CitedVemurafenib Cited
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
CitedUM-164
T4597903564-48-7
UM-164 (DAS-DFGO-II), a highly potent c-Src inhibitor with a dissociation constant (Kd) of 2.7 nM, also effectively inhibits p38α and p38β.
- $30
Size
QTY
Bafetinib Cited
T6311859212-16-1
Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl Lyn inhibitor (IC50: 5.8 19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.
- $31
Size
QTY
CitedTG 100801
T13157867331-82-6In house
TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).
- $84
Size
QTY
SGI-7079
T69821239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
- $35
Size
QTY
Ponatinib Cited
T2372943319-70-8
Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor with IC50 values of 0.37 nM (Abl), 1.1 nM (PDGFRα), 1.5 nM (VEGFR2), 2.2 nM (FGFR1), and 5.4 nM (Src).
- $50
Size
QTY
CitedRepotrectinib Cited
T40711802220-02-5
Repotrectinib (TPX-0005) is a potent ALK ROS1 TRK inhibitor, with IC50 values of 1.01 nM for WT ALK, 5.3 nM for SRC, 1.08 nM for ALK L1196M, and 1.26 nM for ALK G1202R.
- $45
Size
QTY
CitedPD173074 Cited
T2642219580-11-7
PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
- $36
Size
QTY
CitedLyn-IN-1
T11916887650-05-7
Lyn-IN-1 (Bafetinib analog) is a selective, potent dual inhibitor of Bcr-Abl and Lyn.
- $39
Size
QTY
Bosutinib Cited
T0152380843-75-4
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
- $37
Size
QTY
CitedA 419259 trihydrochloride
TQ01321435934-25-0In house
A 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).
- $48
Size
QTY
Fenlean
T31773863193-70-8In house
Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP/prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.
- $119
Size
QTY
BGB-102
T10531807640-87-5
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
- $328
Size
QTY
PF 477736
T6028952021-60-2
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
- $45
Size
QTY
Tolimidone
T689641964-07-2
Tolimidone (NSC 314335) is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals.
- $43
Size
QTY
Scutellarein Cited
T3319529-53-3
Scutellarein (6-Hydroxyapigenin) reduces inflammatory responses by inhibiting Src kinase activity.
- $110
Size
QTY
CitedAP23846
T68455878654-51-4In house
AP23846 is a novel and potent Src family kinase inhibitor that reduces vascular endothelial growth factor and interleukin-8 expression and abrogates downstream angiogenic processes in human solid tumor cell lines.
- $293
Size
QTY
Beta-Hydroxyisovalerylshikonin
TN14407415-78-3
Beta-Hydroxyisovalerylshikonin is an inhibitor of protein-tyrosine kinases such as v-Src and EGFR, and has been shown to induce apoptosis in several human tumor cell lines. Beta-Hydroxyisovalerylshikonin significantly decreased viability of HCT116 cells (IC50 values = 30.9 μg mL).
- $139
Size
QTY
Saracatinib Cited
T6078379231-04-6
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
- $59
Size
QTY
CitedCyt-PTPε Inhibitor-1
T10927428478-94-8In house
Cyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε. Cyt-PTPε Inhibitor-1 blocks the dephosphorylation of c-Src and exhibits anti-osteoclastic activity.
- $58
Size
QTY
PRT062607 hydrochloride
T26961370261-97-4
PRT062607 hydrochloride (P505-15 Hydrochloride) is a selective inhibitor of Syk (IC50: 1 nM). It displays at least 80-fold selectivity for Syk over other kinases.
- $55
Size
QTY
PD-089828
T8976179343-17-0
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 µM)
- $31
Size
QTY
Tirbanibulin Cited
T6345897016-82-9
Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.
- $35
Size
QTY
CitedCSF1R-IN-2
T131942271119-26-5
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
- $38
Size
QTY
1-Naphthyl PP1
T3935221243-82-9
1-Naphthyl PP1 (1-NA-PP 1) is a selective Src inhibitor, targeting v-Src and c-Fyn, c-Abl, CDK2, and CAMK II with IC50 values of 1.0, 0.6, 0.6, 18, and 22 μM, respectively.
- $35
Size
QTY
PP2 Cited
T6266172889-27-9
PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck Fyn (IC50:4 5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
- $39
Size
QTY
CitedCH6953755
T107842055918-71-1
CH6953755 is an orally active, potent and selective YES1 kinase inhibitor (IC50:1.8 nM).CH6953755 has anticancer activity and inhibits cancer cell proliferation by inhibiting YES1 kinase.
- $53
Size
QTY
Rigosertib
T16750592542-59-1
Rigosertib (ON-01910) is a selective, non-ATP-competitive PLK1 inhibitor (IC50: 9 nM) and multi-kinase inhibitor. As a selective anti-cancer agent, Rigosertib induces apoptosis by inhibiting the PI3 kinase Akt pathway, promotes histone H2AX phosphorylation, and induces G2 M arrest in the cell cycle.
- $34
Size
QTY
Dasatinib monohydrate Cited
T1448L863127-77-9
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
- $33
Size
QTY
Citedlavendustin C
T4185125697-93-0
lavendustin C (NSC 666251) is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase.
- $37
Size
QTY
KX2-361
T9411897016-26-1In house
KX2-361 is a orally bioavailable small molecule dual Src tubulin inhibitor that provides long term survival in a murine model of glioblastoma
- $74
Size
QTY
CHIR-124
T6350405168-58-3
CHIR-124 is an effective Chk1 inhibitor (IC50: 0.3 nM). It has 2, 000-fold selectivity against Chk2, 500- to 5, 000-fold less activity against Cdc2 and CDK2/4.
- $35
Size
QTY
NVP-BHG712
T6348940310-85-0
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
- $31
Size
QTY
SU6656
T6997330161-87-0
SU 6656 is a selective inhibitor of Src family kinases, with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
- $34
Size
QTY
PD173955
T3063260415-63-2
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.
- $40
Size
QTY
Ponatinib Hydrochloride
T2372L1114544-31-8
Ponatinib Hydrochloride (AP-24534 Hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
- $39
Size
QTY
ZM 306416
T1754690206-97-4
ZM 306416 (CB 676475), a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).
- $40
Size
QTY
Inulicin
TQ016933627-41-7
Inulicin (1-O-Acetylbritannilactone), an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.
Inquiry
Pelitinib Cited
T2327257933-82-7
Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
- $43
Size
QTY
CitedMasitinib
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
Osteogenic Growth Peptide (10-14) acetate
T37603L
Osteogenic Growth Peptide (10-14) acetate (Osteogenic Growth Peptide) is a Src inhibitor and an effective mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acetate is responsible for the binding to the OGP receptor and activates an intracell
- $227
Size
QTY
CGP77675
T30855234772-64-6In house
CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.
- $43
Size
QTY
Agerafenib
T20701188910-76-0
Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.
- $35
Size
QTY
Go to page 1
Page of 3
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.